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Abstract: Morbid obesity is a lifelong disease, and all patients require complementary follow-up
including nutritional surveillance by a multidisciplinary team after bariatric procedures. Pancreatic
exocrine insufficiency (PEI) refers to an insufficient secretion of pancreatic enzymes and/or sodium
bicarbonate. PEI is a known multifactorial complication after upper gastrointestinal surgery,
and might constitute an important clinical problem due to the large number of bariatric surgical
procedures in the world. Symptoms of PEI often overlap with sequelae of gastric bypass, making the
diagnosis difficult. Steatorrhea, weight loss, maldigestion and malabsorption are pathognomonic for
both clinical conditions. Altered anatomy after bypass surgery can make the diagnostic process even
more difficult. Fecal elastase-1 (FE1) is a useful diagnostic test. PEI should be considered in all patients
after bariatric surgery with prolonged gastrointestinal complaints that are suggestive of maldigestion
and/or malabsorption. Appropriate pancreatic enzyme replacement therapy should be part of the
treatment algorithm in patients with confirmed PEI or symptoms suggestive of this complication.
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1. Introduction
Obesity is the most prevalent metabolic disease worldwide, and represents a global epidemic in
both developed and developing countries [1,2]. Morbid obesity is a lifelong disease, and all patients
undergoing bariatric procedures require complementary follow-up, including nutritional surveillance
by a multidisciplinary team.
Pancreatic secretions play an essential role in digestion, and are controlled by a host of neuronal
and hormonal signaling pathways which modulate not only secretion, but also the cellular integrity of
the gland [3]. Neural regulation of this secretion involves the enteric nervous system in the gut and the
central nervous system. Autonomic nerves of the pancreas form a separate “pancreatic brain”, which is
a part of the enteric nervous system and is responsible for the regulation of the pancreatic secretory
function and pancreatic blood flow [4,5]. Efferent parasympathetic system pathways, consisting of
central dorsal motor nucleus of the vagus and peripheral pancreatic neurons, stimulate exocrine
secretion. Sympathetic innervation of the exocrine pancreas is primarily indirect, and inhibits secretion
by decreasing blood flow and inhibiting transmission in the pancreatic ganglia [5]. Factors controlling
appetite and energy intake also influence the overall digestive function of the gastrointestinal system
involving the pancreas.
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Cholecystokinin (CCK) is known to induce pancreatic exocrine secretion by the activation of CCK1
receptor-mediated signaling pathways, but other hormones also play an important role in pancreatic
function, including ghrelin, leptin, melanocortin, obestatin, apelin, orexin-A and B and glucagon-like
peptide-1 (GLP-1)—Table 1 [3,4,6,7]. GLP-1 and its metabolites have important extrapancreatic effects,
particularly with regard to the cardiovascular system and insulinomimetic effects with respect to
glucose homeostasis. These effects may be particularly important in obesity [6]. Leptin was the first
appetite regulator with an established role in controlling the exocrine pancreas function [8]. Ghrelin is
produced predominantly by the gastric mucosa, and significant elevations were observed in plasma
just before meals, suggesting its role as a hunger signal [7]. Obestatin is a recently identified acid
peptide that appears to have opposite actions to ghrelin on the regulation of food intake, the emptying
of the stomach, and body weight in experimental animals [9]. Apelin is secreted by adipose tissue,
and its production is increased in obesity. In the gastric mucosa, apelin is involved in gastric cell
proliferation, and in controlling exocrine and endocrine functions [10–12].
The presence of nutritional deficiencies in obese individuals before the operation may seem
paradoxical in light of excess caloric intake, but recently published literature has documented that
several micronutrient deficiencies may be present in obese individuals, including adults undergoing
preoperative evaluations for bariatric surgery [13]. The causes of nutritional deficiencies in obese
individuals has not been fully elucidated, but can in large part be explained by the intake of sweet and
high caloric food with poor nutritional quality [14].
Table 1. Role of hormones on pancreatic exocrine function and food intake [4,5,7,15,16].
Hormone Action on Pancreas Exocrine Secretion Action on Food Intake
Cholecystokinin (CCK)
Released from enteroendocrine I cells in
duodenal and ileal mucosa.
Stimulates pancreatic exocrine secretion.
Vagal afferent nerve fibers express
several receptors for CCK.
CCK was the first gut hormone found to
be implicated in appetite control. Some
studies suggest that leptin and CCK may
interact synergistically to induce
short-term inhibition of food intake and
long-term reduction of body weight.
Glucagon-like peptide-1 (GLP-1)
Released from the small intestine;
inhibits hypoglycemia-stimulated
exocrine secretion by direct activation of
dorsal vagal complex.
GLP-1 reduces food intake, suppresses
glucagon secretion and delays gastric
emptying. Intravenous administration of
GLP-1 is associated with
a dose-dependent reduction of food
intake in both normal weight and
obese subjects.
Serotonin
Could activate vagal afferents to initiate
enteropancreatic reflex and to stimulate
pancreatic exocrine secretion.
Vagal afferent nerve fibers express
several receptors for serotonin.
None.
Leptin
Mainly produced and secreted by
adipocytes. Controversial effect on
pancreas. Could activate vagal afferents
to initiate enteropancreatic reflex and
stimulate pancreatic exocrine secretion.
Intravenous application in rats reduces
pancreatic secretion by
inhibiting neurohormonal
CCK-vagal-dependent mechanism.
Leptin administrated in duodenum
significantly stimulates pancreatic
protein secretion.
Significantly reduces the severity of
acute pancreatitis.
Vagal afferent nerve fibers express
several receptors for leptin.
Regulation of food intake, energy
expenditure and body
weight homeostasis.
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Table 1. Cont.
Hormone Action on Pancreas Exocrine Secretion Action on Food Intake
Ghrelin
Controversial effect on pancreas.
Central administration in rats could
activate vagal afferents to initiate
enteropancreatic reflex and to stimulate
pancreatic exocrine secretion.
Intravenous administration in rats
reduced pancreatic enzyme secretion.
Vagus-dependent cholinergic pathway.
Strongly stimulates food intake.
Increases adipogenesis.
Melatonin
Produced in the pineal gland and in the
enteroendocrine cells of gastrointestinal
mucosa and secreted into the duodenal
lumen with the bile.
Protects pancreas against acute damage.
Dose-dependent stimulation of
pancreatic exocrine secretion.
None.
Apelin
Stimulates CCK secretion.
Intravenous application in rats leads to
significant dose-dependent inhibition of
pancreatic secretion. Intraduodenal
application stimulates
pancreatic secretion.
Neurohormonal,
CCK1-vagal-dependent mechanism.
Apelin is expressed in adipose tissue,
suggesting adipokine functions.
Obestatin
May stimulate pancreatic protein output
and trypsin activity following
intravenous and intraduodenal
administration (effect is
dose-dependent).
Appears to have opposite actions to
ghrelin on the regulation of food intake,
emptying the stomach, and body weight
in rodents.
Orexin-A and -B
Stimulation of pancreas exocrine
secretion with orexin-A and no effect
with orexin-B.
Controlled by dorsal vagal complex.
Involved in the control of feeding.
2. Bariatric Surgery
Bariatric surgery is one of the fastest-growing operative procedures performed worldwide, with
more than 500,000 procedures per year [17,18].
Surgery is the most effective treatment for morbid obesity in terms of sustained weight loss,
improvement of comorbidities and quality of life, and in terms of the long-term reduction of overall
mortality [1,19–24].
Surgical techniques are traditionally divided into three groups (see Figure 1) [1,2]:
• food limitation operations (restrictive procedures): vertical-banded gastroplasty, adjustable gastric
banding, proximal gastric bypass and sleeve gastrectomy;
• operations limiting absorption of macronutrients (limiting energy absorption): biliopancreatic
diversion; and
• combined restrictive/malabsorptive operations: biliopancreatic diversion with duodenal switch
or distal gastric bypass.
After bariatric surgery, the risk of possible vitamin and mineral deficiencies needs to be
acknowledged [2]. All bariatric surgery procedures that bypass a portion of the small intestine might
induce nutritional deficiencies. The risk of malabsorption increases proportionally with the length
of bypassed proximal intestine, since this is the primary site of vitamin D, calcium, copper and iron
absorption [13]. Therefore, laboratory follow-up and appropriate supplementation is necessary after
all bariatric procedures [2,13,18,25]. However, despite supplementation, the prevalence of nutritional
deficiencies among bariatric patients is still high, presumably due to low compliance with given
recommendations in many patients [26–31].
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Figure 1. (A) Pre-operative anatomy; (B) Adjustable gastric band with subcutaneous port; (C) 
Vertical-banded gastroplasty; (D) Sleeve gastrectomy; (E) Roux-en-Y gastric bypass; (F) 
Biliopancreatic diversion; (G) Biliopancreatic diversion with gastric sleeve and duodenal switch. 
3. Pancreatic Exocrine Insufficiency 
Pancreatic exocrine insufficiency (PEI) refers to an insufficient secretion of pancreatic enzymes 
(acinar function) and/or sodium bicarbonate (ductal function) [32]. Due to the large reserve capacity 
of the pancreas, “mild” to “moderate” exocrine insufficiency can be compensated for, and overt 
steatorrhea is not expected unless the secretion of pancreatic lipase is reduced to <10% of normal 
levels (“severe”/“decompensated” insufficiency) [33]. Mild PEI is defined as the reduced secretion of 
one or more enzymes with normal bicarbonate concentration in duodenal juice and normal fecal fat 
excretion; moderate PEI is defined as having a reduced enzyme output and bicarbonate 
concentration but normal fecal fat excretion; while severe PEI has a reduced enzyme output and 
bicarbonate concentration plus steatorrhea [34]. Although it is commonly held that steatorrhea is the 
most important clinical manifestation of PEI, some studies have shown reduced absorption of 
fat-soluble vitamins even in patients with mild to moderate exocrine insufficiency [35–37]. Apart 
from post-surgery etiology, the most common underlying causes of PEI are acute and chronic 
pancreatitis, pancreatic neoplasms, celiac disease, diabetes mellitus, haemochromatosis, 
autoimmune diseases and HIV [32].  
In the last 20 years, non-invasive methods have become the gold standards for PEI detection. 
While fecal fat quantification is still considered to be the gold standard, there are many 
disadvantages that limit its clinical applicability. (The collection of the entire stool over 3 days is 
required, which is unpleasant and cumbersome for patients and laboratory staff) [32]. FE1 is a very 
simple test for the indirect and non-invasive evaluation of pancreatic secretion. This test is widely 
available and only requires a small stool sample for analysis. It is widely accepted that the lower the 
FE1 concentration, the higher the probability of PEI. However, guidelines agree that the FE1 test is 
not capable of excluding mild to moderate PEI [33,34]. From a clinical perspective, it is very 
important that FE1 is determined in a solid stool, which significantly reduces the number of falsely 
low FE1 levels. FE1 levels in a watery stool could be false positives if the process of lyophilization is 
not performed [38]. 13C mixed triglyceride breath test (13C-MTG-BT) offers an alternative to FE1, but 
is not widely available [33]. 
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3. Pancreatic Exocrine Insufficiency
Pancreatic exocrine insufficiency (PEI) refers to an insufficient secretion of pancreatic enzymes
(acinar function) and/or sodium bicarbonate (ductal function) [32]. Due to the large reserve capacity
of the pancre s, “mild” to “moderate” exocri e insufficiency can be compensated for, and overt
steatorrhea i not xpected unless the secretion of pancreatic lipase is r uced to <10% of normal levels
(“severe”/“decompensated” i sufficiency) [33]. Mild PEI is defined as the reduced secretion of one or
more enzymes with normal bicarbonate concentration in duodenal juice and normal fecal fat excretion;
moderate PEI is defined as having a reduced enzyme output and bicarbonate concentration but normal
fecal fat excretion; while severe PEI has a reduced enzyme output and bicarbonate concentration
plus steatorrhea [34]. Although it is commonly held that steatorrhea is the most important clinical
manifestation of PEI, some studies have shown reduced absorption of fat-soluble vitamins even in
patients with mild to moderate exocrine insufficiency [35–37]. Apart from post-surgery etiology, the
most com on und rlying causes of PEI are acute and chronic pancreatitis, pancreatic neoplasms,
celiac disease, diabetes mellitus, haemochromatosis, autoi mune diseases nd HIV [32].
In th last 20 years, non-invasive methods have become the gold standards for PEI detection.
While fecal fat quantification is still considered to be the gold standard, there are many disadvantages
that limit its clinical applicability. (The collection of the entire stool over 3 days is required, which is
unpleasant and cumbersome for patients and laboratory staff) [32]. FE1 is a very simple test for the
indirect and non-invasive evaluation of pancreatic secretion. This test is widely available and only
requires a small stool sample for analysis. It is widely accepted that the lower the FE1 concentration,
the higher the probability of PEI. However, guidelines agree that the FE1 test is not capable of excluding
mild t moderate PEI [33,34]. From a clinical persp ctiv , it is ry impo tant that FE1 is determined
in a s lid st ol, which significantly r duces the number of falsely low FE1 levels. FE1 levels in
a watery stool could be false positives if the process of lyophilization is not performed [38]. 13C mixed
triglyceride breath test (13C-MTG-BT) offers an alternative to FE1, but is not widely available [33].
The secretin-enhanced magnetic resonance cholangiopancreatography (s-MRCP) technique
reveals ductal morphological alterations, simultaneously gives semi-quantitative information on
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functional changes, and is probably the most appropriate morphological test for the assessment of
pancreatic exocrine function [39].
4. Exocrine Pancreatic Function after Digestive Surgery
PEI is a known and common complication after pancreatic and gastric surgery. Nakamura et al.
performed a 13C-labeled mixed triglyceride breath test on 61 patients after pancreatoduodenectomy
(PD) and found PEI in 62% of patients [40]. Gastrectomy is an important additional factor that
influences the exocrine function, but also influences the digestive process in its complexicity [41].
It is known that even partial gastrectomy leads to impaired release of gastrin, pancreatic polypeptide
(PP) and cholecystokinin (CCK) [42,43]. Malfertheiner et al. performed a study on rats in order
to investigate adaptive changes of the exocrine pancreas occurring after distal gastric resection
by different procedures (Billroth I and Billroth II) and showed that both procedures induced an
organotrophic effect on the pancreas after two weeks [42]. Trophism of the exocrine pancreas
in the same study was associated with an increase of amylase and trypsin, whereas lipase was
not affected. It is known that afferent and efferent loop syndromes can develop following gastric
surgery procedures, which might result in accelerated intestinal transit time, as well as colonization
by pathogenic bacteria in the upper gastrointestinal tract with inadequate stimulation and poorly
synchronized pancreatic enzyme secretion [32]. This condition is known as postcibal asynchrony
and can cause PEI. As digestive products are stronger endogenous stimulators of CCK release and
of pancreatic secretion than macronutrients, postcibal asynchrony is also associated with decreased
endogenous stimulation [44]. However, it seems that postcibal asynchrony is just one causative factor.
In addition to reducing the resorptive surface by diverting the passage of food from digestive juices
via long Roux-Y- limbs, all instances of exocrine pancreatic function are affected: release, activation,
degradation and effectiveness [45]. Since experimental data on animals indicated that the stomach
plays an important role in the regulation of the exocrine pancreas, further studies on humans have
confirmed that hypothesis [43,46]. Gullo et al. retrospectively evaluated exocrine pancreatic function in
12 patients after total gastrectomy [46]. The secretion of bicarbonate, lipase, and chymotrypsin into the
duodenum in response to exogenous stimulation with secretin was significantly lower in patients after
gastrectomy than in controls, and eight of the 12 patients (67%) had steatorrhea. Friess and colleagues
prospectively investigated the influence of total gastrectomy on exocrine function in 15 patients,
analyzing pancreatic function before and three months after surgery using the secretin-cerulein
test and analysis of gastrointestinal hormone levels [43]. After total gastrectomy, patients develop
severe primary PEI with decreased gastrin, decreased late postprandial PP and increased CCK levels.
The authors concluded that the described hormonal changes may explain why many patients with
total gastrectomy have maldigestion and weight loss postoperatively, and proposed pancreatic enzyme
replacement therapy to avoid these symptoms. Armbrecht et al. evaluated the effect of peroral
pancreatic enzyme replacement therapy (PERT) on abdominal symptoms, bowel habits, fecal fat
excretion and oro-caecal transit time in patients after total gastrectomy for carcinoma of the stomach
with Roux-en-Y anastomosis. They concluded that PERT reduces massive steatorrhea and improves
stool consistency [47].
In one study including 22 patients one year after bariatric surgery (Roux-en-Y or mini-omega
loop gastric bypass), exocrine pancreatic function was evaluated with fecal elastase-1 (FE1) levels. PEI
was found in 9.1% of patients [48]. In addition, patients with low FE1 levels underwent magnetic
resonance imaging (MRI) of the pancreas and measurement of serum nutritional markers. There were
no signs of chronic pancreatitis, but at least one serological nutritional marker was below the lower
limit of normal in all of the tested patients (vitamin D, vitamin A, selenium, prealbumin, zinc, copper,
folic acid and iron) despite routine vitamin and mineral replacement therapy after surgery [48].
In a recently published study, 188 consecutive patients were followed for 52 months after
bariatric surgery (distal and proximal Roux-en-Y gastric bypass), and exocrine pancreatic function
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was evaluated by clinical symptoms, FE1 and positive dechallenge-rechallenge test with pancreatic
enzyme replacement therapy [45]. 31% of these patients were diagnosed with PEI.
As to the other forms of bariatic surgery, the likelihood of PEI after gastric banding (Figure 1B,C)
is low since there are no anatomical changes or surgical manipulation of the gastric wall. After sleeve
gastrectomy (Figure 1D), the neuronal network is impaired, and a certain degree of PEI can be expected;
however, clinical studies are missing.
5. Conclusions
Due to the high levels of incidence after various types of bariatric surgery and the large
number of bariatric surgical procedures performed, postoperative PEI might be an important clinical
problem. Symptoms of PEI often overlap with sequelae of gastric bypass, making the diagnosis
difficult. Steatorrhea, weight loss, maldigestion and malabsorption are pathognomonic for both
clinical conditions. Altered anatomy after bypass surgery can make the diagnostic process even more
difficult. Evidence suggests that the FE-1 monoclonal test is reliable for the evaluation of pancreatic
function in many pancreatic and non-pancreatic disorders. It is non-invasive, less time-consuming,
and unaffected by pancreatic enzyme replacement therapy. Although it cannot be considered the
gold-standard method for the functional diagnosis of PEI, the advantages of the FE-1 test make it
a very appropriate test for screening patients who may be at risk of this disorder [49]. Nutritional
serum markers should be measured and PEI should be considered in all patients after bariatric surgery
with prolonged gastrointestinal complaints and/or malabsorption. Appropriate pancreatic enzyme
replacement therapy should be part of the treatment algorithm in patients with confirmed PEI or
symptoms suggestive of this complication. More studies regarding the clinical implications of PEI after
bariatric surgery, as well as more information about the prevalence of PEI in morbidly obese patients,
is warranted.
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